Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cafestol is a natural diterpenoid molecule found in coffee beans, particularly in unfiltered coffee such as French press and Turkish coffee[1][3]. It is known for its diverse biological activities, including raising serum cholesterol levels by inhibiting bile acid synthesis through downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase[5][6]. Cafestol acts as an agonist ligand for nuclear receptors such as farnesoid X receptor (FXR) and pregnane X receptor (PXR), affecting cholesterol homeostasis[1][4]. Beyond its impact on lipid metabolism, cafestol exhibits anti-inflammatory, anticarcinogenic, hepatoprotective, antidiabetic, and neuroprotective properties. Mechanistically, it can increase glucose-stimulated insulin secretion and glucose uptake in muscle cells; it also modulates inflammatory mediators via pathways like Nrf2/HO-1 and Sirt1 activation[2][3]. Cafestol has shown potential benefits in models of cancer prevention and neuroprotection (e.g., Parkinson’s disease models)[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cafestol.